ALTIMMUNE, INC. (ALT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 12.50M USD | Liabilities, Current |
| Cash and equivalents | 63.01M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 263.27M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $12.50M | $63.01M | $263.27M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $11.32M | $97.60M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $15.00M | $43.76M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $12.61M | $61.24M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $9.22M | $183.10M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $9.80M | $49.10M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.47M | $36.93M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $8.64M | $31.47M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $15.15M | $57.13M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.33M | $78.98M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $12.14M | $135.12M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $11.87M | $86.86M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $11.44M | $102.35M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $14.95M | $104.69M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $17.05M | $111.10M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $15.74M | $127.47M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $13.85M | $135.86M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $19.12M | $179.95M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $18.28M | $190.30M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $19.13M | $174.86M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $9.10M | $174.10M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $9.82M | $149.93M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.02M | $115.92M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.29M | $143.50M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $4.92M | $64.74M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $6.05M | $11.28M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $3.92M | $8.96M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $2.47M | $10.97M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $3.48M | $41.67M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $3.68M | $44.30M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $4.53M | $33.72M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $8.34M | $7.96M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $7.07M | $4.17M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $5.16M | $4.56M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.84M | $8.77M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $4.18M | $17.12M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $5.53M | $8.37M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.23M | $15.78M | (m) | $1.00M | (m) | (m) |
| 2016-12-31 | (m) | $204.84M | $153.99M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $3.73M | $69.11M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $3.27M | $23.16M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $2.64M | $14.24M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.18M | $15.57M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $2.38M | $17.39M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.34M | $18.41M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $4.54M | $15.72M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.58M | $18.64M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $3.88M | $19.62M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $2.83M | $11.27M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $3.47M | $9.53M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $6.80M | $10.48M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $5.41M | $15.94M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $7.72M | $15.79M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $7.79M | $12.87M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $7.49M | $12.70M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $6.97M | $14.73M | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $5.66M | $11.78M | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $5.31M | $15.30M | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $4.62M | $11.24M | (m) | $4.87M | (m) | (m) |
| 2011-09-30 | (m) | $3.69M | $10.41M | (m) | $4.04M | (m) | (m) |
| 2011-06-30 | (m) | $5.93M | $14.16M | (m) | $4.38M | (m) | (m) |
| 2011-03-31 | (m) | (m) | $9.71M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | $6.16M | $11.79M | (m) | $5.37M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $2.72M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $682.00K | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | $2.67M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |